Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.

• Tác giả: Rebecca Arend, Floor Backes, Victoria Bae-Jump, Bradley Corr, Casey Cosgrove, Sarah Crafton, Linda Duska, Kari Hacker, Paulina J Haight, Amanda Jackson, Emily Ko, Gottfried E Konecny, Thomas Krivak, Olivia Lara, Kathleen Moore, Mary M Mullen, Bhavana Pothuri, Marilyn Sanchez, Angeles Secord, Carson Smitherman, Premal H Thaker, Samantha M Thomas, Christina Washington, Jason Wright
• Ngôn ngữ: eng
• Ký hiệu phân loại: 738.13 Apparatus and equipment
• Thông tin xuất bản: United States : Gynecologic oncology , 2025
• Bộ sưu tập: NCBI
• ID: 551703

Tóm tắt

 OBJECTIVE: We sought to determine the association between platinum-free interval (PFI) and response to retreatment with platinum-based chemotherapy vs lenvatinib/pembrolizumab in patients with recurrent endometrial cancer. METHODS: Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium patients with recurrent disease were included in this retrospective analysis if they received first-line treatment with platinum-based chemotherapy (adjuvant or first recurrence), followed by second-line re-treatment with platinum or lenvatinib/pembrolizumab. PFI was defined as time between date of last platinum to start date of second-line therapy. Patients were stratified according to PFI ≤12 months or >
  12 months. Overall response rate (ORR) to second-line treatment was estimated after stratification by PFI. RESULTS: Of 217 patients, 146 (67 %) underwent retreatment with platinum and 71 (33 %) were treated with lenvatinib/pembrolizumab. 127 (59 %) had PFI ≤12 months, and 84 (39 %) patients had PFI >
 12 months. Patients treated with platinum had longer PFI than those treated with lenvatinib/pembrolizumab (median PFI 12.9 vs 4.6 months
  p <
  0.001). ORR was 58 % vs 49 % for platinum vs lenvatinib/pembrolizumab (p = 0.27). For all patients, ORR was 68 % vs 47 % with PFI >
 12 months and ≤ 12 months, respectively (p = 0.002). At each PFI, ORR was similar regardless of treatment with platinum or lenvatinib/pembrolizumab (PFI ≤12 months ORR 49 % vs 44 % respectively, p = 0.75
  PFI >
 12 months ORR 67 % vs 75 % respectively, p = 0.74). CONCLUSION: Longer PFI is associated with improved response to second-line treatment in patients with recurrent endometrial cancer. Despite utilization of PFI for real-world treatment decisions, it was not found to predict response between regimens at any given PFI.